← Leaderboards
David G. Nathan
Dana-Farber Cancer Institute
$5,920,675
Attributed
$18,199,136
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2009–16$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$28,565,451 · 7
By mechanism
P50$20,457,740 · 3
R01$4,049,591 · 1
RC2$1,817,442 · 1
P30$1,558,610 · 1
R34$682,068 · 1
Top collaborators
- Joshua Jeffrey Field12 shared
- Joel M. Linden12 shared
- Jonathan R Lindner5 shared
- Donna S. Neuberg4 shared
- Klaus F. Ley2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Colin A Sieff$2,137,288
- Eva C Guinan$4,120,977
- Akiko Shimamura$14,324,270
- Hanna Gazda$261
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelAgonistBloodReceptorIschemiaClinical TrialsInflammationCellsSickle Cell AnemiaSeveritiesLeukocytesLungInjuryCollaborationsSickle CellEventPrincipal InvestigatorPainFda ApprovedPharmaceutical PreparationsBlood FlowAcute Chest SyndromeInstitutionBase
Grant awards (23)
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,004,198
P50 · FY2016 · HL · contact PI
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$799,323
R01 · FY2016 · HL
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,108,843
P50 · FY2015 · HL · contact PI
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$787,224
R01 · FY2015 · HL
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,181,100
P50 · FY2014 · HL · contact PI
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$788,408
R01 · FY2014 · HL
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,220,754
P50 · FY2013 · HL · contact PI
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$770,409
R01 · FY2013 · HL
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,282,414
P50 · FY2012 · HL · contact PI
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$904,227
R01 · FY2012 · HL
A Feasibility Study of Regadenoson for the Treatment of Acute Chest Syndrome$341,034
R34 · FY2012 · HL · contact PI
A Feasibility Study of Regadenoson for the Treatment of Acute Chest Syndrome$341,034
R34 · FY2011 · HL · contact PI
CTRIP: Treatment of Sickle Cell Crisis with inhibitors of NKT cell activation$948,786
RC2 · FY2010 · HL · contact PI
CTRIP: Treatment of Sickle Cell Crisis with inhibitors of NKT cell activation$868,656
RC2 · FY2009 · HL · contact PI
STEM CELL THERAPY OF CONGENITAL DEFECTS IN HEMATOPOIESIS$1,838,132
P50 · FY2004 · HL
STEM CELL THERAPY OF CONGENITAL DEFECTS IN HEMATOPOIESIS$1,793,037
P50 · FY2003 · HL
STEM CELL THERAPY OF CONGENITAL DEFECTS IN HEMATOPOIESIS$1,753,867
P50 · FY2002 · HL
CORRECTION OF CONGENITAL DISEASES BY STEM CELL THERAPY$284,242
P50 · FY2002 · HL
STEM CELL THERAPY OF CONGENITAL DEFECTS IN HEMATOPOIESIS$1,717,217
P50 · FY2001 · HL
CORRECTION OF CONGENITAL DISEASES BY STEM CELL THERAPY$284,242
P50 · FY2001 · HL
STEM CELL THERAPY OF CONGENITAL DEFECTS IN HEMATOPOIESIS$1,705,452
P50 · FY2000 · HL
CANCER CENTER SUPPORT GRANT$1,558,610
P30 · FY2000 · CA
CORRECTION OF CONGENITAL DISEASES BY STEM CELL THERAPY$284,242
P50 · FY2000 · HL